APA引文

NAKAMOTO, S., WATANABE, J., OHTANI, S., MORITA, S., & IKEDA, M. (2020). Bevacizumab as First-line Treatment for HER2-negative Advanced Breast Cancer: Paclitaxel plus Bevacizumab Versus Other Chemotherapy. In Vivo.

Citação norma Chicago

NAKAMOTO, SHOGO, JUNICHIRO WATANABE, SHOICHIRO OHTANI, SATOSHI MORITA, and MASAHIKO IKEDA. "Bevacizumab As First-line Treatment for HER2-negative Advanced Breast Cancer: Paclitaxel Plus Bevacizumab Versus Other Chemotherapy." In Vivo 2020.

MLA引文

NAKAMOTO, SHOGO, et al. "Bevacizumab As First-line Treatment for HER2-negative Advanced Breast Cancer: Paclitaxel Plus Bevacizumab Versus Other Chemotherapy." In Vivo 2020.